BiotechTube
Biotest Pharmaceuticals

Biotest Pharmaceuticals

Dreieich, Germany· Est.
biotest.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $300M

Overview

Biotest Pharmaceuticals is a long-established, revenue-generating commercial biopharma company focused on plasma-derived biologics. It maintains a vertically integrated model, controlling plasma collection through its own network of centers. The company has a commercial portfolio for immunology, haematology, and intensive care, and is advancing a late-stage pipeline including next-generation immunoglobulins and novel therapies like Trimodulin for severe pneumonia.

Clinical ImmunologyHaematologyIntensive Care Medicine

Technology Platform

Proprietary plasma fractionation and purification for immunoglobulins (IgG, IgM), coagulation factors, hyperimmunoglobulins, and albumin. Developing next-generation IgG formulations and novel multi-immunoglobulin therapies.

Funding History

1
Total raised:$300M
Debt$300M

Opportunities

The global plasma-derived therapy market offers steady growth, particularly for next-generation, more convenient products like Yimmugo.
Trimodulin represents a major breakthrough opportunity in the vast, high-unmet-need market of severe community-acquired pneumonia.
Vertical integration provides a stable plasma supply and cost advantages.

Risk Factors

High competition from larger plasma players pressures pricing and market share.
Clinical and regulatory failure of key pipeline assets, especially Trimodulin, would significantly impact growth.
The business is vulnerable to plasma collection disruptions and stringent manufacturing compliance requirements.

Competitive Landscape

Biotest competes in the global plasma protein therapeutics market against large-cap leaders like Takeda, CSL Behring, Grifols, and Octapharma. It differentiates through niche products (IgM-enriched Ig, specific hyperimmunes) and vertical integration. Its pipeline aims to compete in core immunoglobulin and novel acute care markets.

More companies in Biologics / Biosimilars →More companies in Germany →